top of page

Alopecia Help

PRP for Patchy Alopecia Areata: What Does New Research Tell Us?

Writer: Gwen Adey
Gwen Adey
10 hours ago
4 min read

Could platelet-rich plasma (PRP) help people with alopecia areata? A new clinical trial has compared PRP with steroid injections, one of the established treatments for this type of hair loss.


Alopecia areata is an autoimmune condition in which the immune system mistakenly targets hair follicles, causing hair to fall out. It often appears as one or more smooth, round patches of hair loss, although some people experience more extensive shedding.


For people living with alopecia areata, finding an effective treatment can be challenging. Hair sometimes regrows spontaneously, while in other cases the condition persists or returns.


Steroid injections are commonly used to treat small patches of alopecia areata, but researchers are also investigating whether platelet-rich plasma (PRP) could offer another approach.



What did the researchers investigate?


The study involved 60 adults with localised alopecia areata affecting less than 25% of their scalp.


Participants were randomly assigned to receive one of two treatments:

  • PRP injections: Platelet-rich plasma prepared from the patient’s own blood.

  • Steroid injections: Triamcinolone acetonide, a corticosteroid commonly used to treat patchy alopecia areata.


Both groups received three treatment sessions, spaced three weeks apart.


The researchers assessed hair regrowth, changes in the extent of hair loss, side effects and patient satisfaction. They also followed participants to 18 weeks to look for signs of relapse.


What did the study find?


Both groups experienced improvements in hair growth.

By nine weeks, complete hair regrowth was observed in:

  • 46.7% of patients receiving steroid injections

  • 33.3% of patients receiving PRP


Although complete regrowth was more common in the steroid group, the difference was not statistically significant.


The researchers also measured the extent of hair loss using the Severity of Alopecia Tool (SALT), a standardised scoring system.

Both groups showed improvements, with no statistically significant difference between treatments.


Interestingly, fully pigmented hair regrowth was observed in 73.3% of PRP patients compared with 60% of those receiving steroid injections.

Again, however, this difference was not statistically significant.


Overall, the findings suggest that PRP may have potential as a treatment for localised alopecia areata, although larger studies are needed before we can draw firm conclusions about how it compares with established treatments.


What about side effects?


The two treatments had different side-effect profiles.


Patients receiving PRP experienced more pain and bleeding at the injection sites.


However, some side effects associated with corticosteroid injections were observed only in the steroid group.

These included:

  • Skin atrophy: Thinning or indentation of the skin at the injection site.

  • Telangiectasia: The appearance of small, visible blood vessels.


By nine weeks, skin atrophy had been observed in 16.7% of patients receiving steroid injections, compared with none in the PRP group.


This is an interesting distinction, although the study was too small to establish reliable differences in the frequency of less common complications.


Did the hair loss return?


Alopecia areata can be unpredictable, and regrowth does not necessarily mean the condition has resolved permanently.


At the 18-week follow-up, the researchers reported relapse in 20% of the steroid group and 10% of the PRP group.


This difference was not statistically significant, and the follow-up period was relatively short.


Longer-term research is needed to understand whether either treatment produces more sustained regrowth.


Why might PRP help?


PRP is prepared by taking a small sample of a patient’s blood and processing it to concentrate the platelets. Platelets contain growth factors and signalling molecules involved in tissue repair and cellular activity. These substances may influence several processes relevant to hair growth, including blood vessel formation and hair follicle activity.


However, alopecia areata is fundamentally an immune-mediated condition.

Although PRP may support aspects of follicle function, its effects on the abnormal immune response responsible for alopecia areata are not yet fully understood.


This is an important distinction. Encouraging hair growth and addressing the underlying cause of hair loss are not necessarily the same thing.


How strong is the evidence?


This was a randomised controlled trial, which is a useful study design for comparing treatments.


However, several limitations are worth considering.


First, the study included only 60 patients, all with relatively limited scalp involvement. Its findings cannot automatically be applied to people with extensive or longstanding alopecia areata.


Second, the researchers followed patients for only 18 weeks. Alopecia areata can relapse months or years after apparent recovery, so longer follow-up is important.


Third, alopecia areata sometimes improves spontaneously, particularly when it is recent and limited in extent. Because the study did not include an untreated or placebo group, it cannot tell us how much of the observed regrowth was attributable to treatment rather than the natural course of the condition.


Finally, finding no statistically significant difference between treatments does not prove that they are equally effective.


The study adds to the evidence that PRP deserves further investigation, but it does not establish PRP as an equivalent replacement for steroid injections.


What does this mean for people with alopecia areata?


The encouraging finding is that hair regrowth occurred in both treatment groups.


For people with small patches of alopecia areata, steroid injections remain an established treatment option. PRP is still being investigated, and the evidence is not yet strong enough to recommend it routinely in place of established therapies.


Treatment decisions also depend on the extent and activity of the condition, previous treatments, individual circumstances and patient preferences.


Importantly, not all patchy hair loss is alopecia areata. Other conditions can produce a similar appearance but require very different management.


Understanding the cause of hair loss is therefore an essential first step.


Final thoughts


Research into hair loss treatments continues to evolve, and studies like this help us understand where newer approaches might fit alongside established therapies.


PRP has a large evidence base for androgenetic alopecia. Its potential role in alopecia areata is less well established, but this study provides another useful piece of evidence.


The findings are promising enough to justify further research, while reminding us that a treatment showing potential is not the same as a treatment being proven effective.


For anyone experiencing unexplained hair loss, obtaining an accurate diagnosis remains one of the most valuable steps towards understanding the options available.


Research reference

Sethi Y, Dabas G, Yadav P, Sagar V, Chhabra G. (2026). Comparison of Platelet-Rich Plasma Therapy Versus Intralesional Triamcinolone Acetonide in the Treatment of Alopecia Areata: A Single-Blinded, Randomised Controlled Trial. Indian Journal of Dermatology, 71, 451–458.


Authored by: Dr Gwen Adey

First Published: 15/11/26

bottom of page